Response to first-line therapies for MPN-AP/BP
| Therapy . | 2017 ELN response . | 2012 MPN-BP response . |
|---|---|---|
| IC (n = 65) | CR: 28% CRi: 14% MLFS: 2% PR: 11% TF: 45% | CCR: 8% ALR-C: 29% ALR-P: 20% SD: 10% PD: 17% |
| (n = 65 evaluable for ELN) | ||
| (n = 51 evaluable for MPN-BP) | ||
| DNMTi + VEN based (n = 54) | CR: 22% CRi: 19% MLFS: 6% PR: 4% SD: 17% TF: 32% | CCR: 2% ALR-C: 37% ALR-P: 20% SD: 15% PD: 27% |
| (n = 54 evaluable for ELN) | ||
| (n = 42 evaluable for MPN-BP) | ||
| DNMTi based (n = 65) | CR: 9% CRi: 11% MLFS: 2% PR: 9% SD: 32% TF: 37% | CMR: 6% CCR: 2% ALR-C: 14% ALR-P: 12% SD: 37% PD: 33% |
| (n = 65 evaluable for ELN) | ||
| (n = 49 evaluable for MPN-BP) | ||
| Targeted monotherapy (n = 4) | CRi: 25% SD: 50% TF: 25% | ALR-P: 50% SD: 50% |
| (n = 4 evaluable for ELN) | ||
| (n = 4 evaluable for MPN-BP) | ||
| Other therapies (n = 6) | CRi: 17% PR: 17% SD: 17% TF: 30% | ALR-C: 17% ALR-P: 17% SD: 33% PD: 33% |
| (n = 6 evaluable for ELN) | ||
| (n = 6 evaluable for MPN-BP) |
| Therapy . | 2017 ELN response . | 2012 MPN-BP response . |
|---|---|---|
| IC (n = 65) | CR: 28% CRi: 14% MLFS: 2% PR: 11% TF: 45% | CCR: 8% ALR-C: 29% ALR-P: 20% SD: 10% PD: 17% |
| (n = 65 evaluable for ELN) | ||
| (n = 51 evaluable for MPN-BP) | ||
| DNMTi + VEN based (n = 54) | CR: 22% CRi: 19% MLFS: 6% PR: 4% SD: 17% TF: 32% | CCR: 2% ALR-C: 37% ALR-P: 20% SD: 15% PD: 27% |
| (n = 54 evaluable for ELN) | ||
| (n = 42 evaluable for MPN-BP) | ||
| DNMTi based (n = 65) | CR: 9% CRi: 11% MLFS: 2% PR: 9% SD: 32% TF: 37% | CMR: 6% CCR: 2% ALR-C: 14% ALR-P: 12% SD: 37% PD: 33% |
| (n = 65 evaluable for ELN) | ||
| (n = 49 evaluable for MPN-BP) | ||
| Targeted monotherapy (n = 4) | CRi: 25% SD: 50% TF: 25% | ALR-P: 50% SD: 50% |
| (n = 4 evaluable for ELN) | ||
| (n = 4 evaluable for MPN-BP) | ||
| Other therapies (n = 6) | CRi: 17% PR: 17% SD: 17% TF: 30% | ALR-C: 17% ALR-P: 17% SD: 33% PD: 33% |
| (n = 6 evaluable for ELN) | ||
| (n = 6 evaluable for MPN-BP) |
ALR-P, acute leukemia response–partial; CCR, complete cytogenetic response; CMR, complete molecular response; PD, progressive disease; PR, partial remission.